Saturday 17 October 2026 Export NBTX’s income statement to Excel — free account

Nanobiotix S.A. - Sponsored ADR

21.30 0.93 −4.18%

Follow NBTX

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: 3.40
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1,130.00

Revenue 0.10

Net Income (130.50)

Free Cash Flow (87.24)

Net Debt (128.93)

Current Ratio 1.44

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 4,254.38

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (6.16%)

Next Y EPS Growth 63.63%

Next Y revenue growth —

Next 5Y EPS Growth 30.10%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 85.15%

10-year low 10-year high

EV/Sales against its own 10 years 82.15%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	81	54	60	129
Receivables	1	3	2	2
Inventory	—	—	—	—
Other	12	9	9	12
	95	67	71	144

	2023	2024	2025	Q'26
Payables	20	22	10	10
ST’ Debt	—	—	—	—
Other	34	42	55	90
	54	64	65	100

Compound Annual Growth %

	10y	5y	3y
Sales	—	66.64%	94.24%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	37
’24	—	—	—	—	—
’23	—	—	—	—	39
’22	—	—	—	—	5
’21	—	—	—	—	3
’20	—	—	—	—	3

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(38)
’24	—	—	—	—	(21)
’23	—	—	—	—	(14)
’22	—	—	—	—	(39)
’21	—	—	—	—	(35)
’20	—	—	—	—	(31)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(20)	—	(38)	(38)
’24	—	(7)	—	(22)	(22)
’23	—	(19)	—	(14)	(14)
’22	—	(19)	—	(39)	(39)
’21	—	(18)	—	(36)	(36)
’20	—	(14)	—	(32)	(32)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(0.57)
’24	—	—	—	—	(1.56)
’23	—	—	—	—	(1.17)
’22	—	—	—	—	(1.76)
’21	—	—	—	—	(1.60)
’20	—	—	—	—	(1.60)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	15.89	6.51	2.32	1.75	2.76	2.82	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	21.55	20.63	10.42	11.00	8.96	30.35
People
People	Employees	—	—	—	90	88	100	102	102	108	97
	Revenue/emp, $m	0.00	0.00	0.00	0.03	0.03	0.03	0.05	0.38	(0.07)	0.38
Income, $m
Income, $m	Revenue	2	0	0	3	3	3	5	39	—	37
	Gross margin, %	0.00	(37.14)	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(27)	(35)	(39)	(57)	(38)	(56)	(60)	(43)	(74)	(27)
	EBT margin, %	(1,636.19)	(11,667.74)	(28,962.07)	(2,003.63)	(1,336.80)	(1,775.50)	(1,194.12)	(109.32)	946.06	(73.51)
	Net income	(23)	0	(35)	(57)	(38)	(56)	(60)	(43)	(74)	(27)
	Depreciation	1	0	1	2	2	2	2	2	2	2
Per share, $
Per share, $	Revenue	0.11	0.02	0.01	0.13	0.12	0.09	0.14	1.06	(0.16)	0.77
	Earnings	(1.51)	(1.81)	(1.78)	(2.63)	(1.60)	(1.60)	(1.76)	(1.17)	(1.56)	(0.57)
	Cash flow	(1.26)	(1.46)	(1.13)	(2.13)	(1.29)	(1.02)	(1.12)	(0.37)	(0.45)	(0.79)
	Capex	0.00	0.00	0.00	(0.07)	0.00	(0.01)	0.00	(0.01)	(0.02)	(0.01)
	Free cash flow	(1.26)	(1.46)	(1.13)	(2.21)	(1.29)	(1.03)	(1.12)	(0.38)	(0.47)	(0.80)
	Book value	1.18	3.01	0.61	(0.10)	3.30	0.91	(0.82)	(0.05)	(1.50)	(2.00)
	Shares, m	15	17	27	22	24	35	35	37	47	48
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2,115.07	2,115.07	2,115.07	2,115.07	2,557.11	1,617.86	741.02	1,468.06	573.24	4,617.90
	P/B	0.00	0.00	0.00	0.00	4.27	5.33	0.00	0.00	0.00	0.00
	EV/Sales	2,239.44	2,239.44	2,239.44	2,239.44	1,917.58	1,146.44	803.15	1,167.28	537.50	4,526.00
	EV/FCF	(3.81)	(3.81)	(3.81)	(3.81)	(2.22)	(1.20)	(0.75)	(1.34)	(0.91)	(5.41)
Cash, $m
Cash, $m	Operating cash flow	(19)	(25)	(30)	(46)	(31)	(35)	(39)	(14)	(21)	(38)
	Capex	0	(2)	(1)	(2)	0	0	0	0	(1)	(1)
	Free cash flow	(19)	(25)	(30)	(48)	(32)	(36)	(39)	(14)	(22)	(38)
Balance, $m
Balance, $m	Working capital	20	53	36	36	121	67	15	41	3	6
	Total debt	6	6	24	50	60	52	57	—	—	—
	Net debt	(16)	(51)	(18)	(39)	(136)	(99)	(44)	(81)	(54)	(60)
	Shareholders’ equity	18	53	16	(2)	80	32	(28)	(2)	(71)	(96)
Returns, %
Returns, %	ROA	(45.76)	(198.42)	(82.41)	(98.45)	(35.52)	(40.66)	(65.55)	(52.21)	(84.46)	(36.24)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(65.20)	(89.17)	(101.46)	(812.85)	(97.94)	(99.13)	(3,754.04)	281.84	201.73	32.53

Negative figures in brackets.

value withheld pending a data check

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2019 · fundamentals updated 28 Sep 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DRTS Alpha Tau Medical Ltd.	$1.2B	— (loss-making)	—	—	n/m	−30.42% (below 0%: shrinking)	0.00%	0.00%	Compare
LBRX LB Pharmaceuticals Inc	$1.2B	— (loss-making)	—	—	n/m	−579.03% (below 0%: shrinking)	—	0.00%	Compare
BCAX Bicara Therapeutics Inc.	$1.2B	— (loss-making)	—	—	n/m	−72.95% (below 0%: shrinking)	—	0.00%	Compare
DMRA Galecto, Inc.	$1.2B	— (loss-making)	—	—	n/m	−877.51% (below 0%: shrinking)	0.00%	0.00%	Compare
VOR Vor Biopharma Inc.	$1.1B	— (loss-making)	—	—	n/m	−47.59% (below 0%: shrinking)	0.00%	—	Compare
NBTX Nanobiotix S.A. - Sponsored ADR	$1.1B	— (loss-making)	—	−71.69% (below 0%: shrinking)	n/m	−177.26% (below 0%: shrinking)	0.00%	0.00%
REPL Replimune Group, Inc.	$1.1B	— (loss-making)	—	—	n/m	+5.04% (above 0%: growing)	0.00%	0.00%	Compare
IMTX Immatics N.V.	$1.1B	— (loss-making)	— (loss-making)	+97.71% (above 0%: growing)	n/m	−44.41% (below 0%: shrinking)	100.00%	(734.95%)	Compare
JANX Janux Therapeutics, Inc.	$1.1B	— (loss-making)	— (loss-making)	+2,238.72% (above 0%: growing)	n/m	+150.57% (above 0%: growing)	100.00%	(308.66%)	Compare
Median of peers	$1.2B	—	—	—	—	−46.00%	0.00%	0.00%

All 614 Biotechnology stocks →

Nanobiotix S.A. - Sponsored ADR (NBTX) key facts

Nanobiotix S.A. - Sponsored ADR (NBTX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, NBTX traded at $21.30, a market capitalization of $1.1 billion.
Return on equity was 32.5% and debt-to-equity 0.00.
Its Altman Z-score is 3.40 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 28, 2026.